Effects of α‐Glucosidase Inhibition and Viscous Fibre on Diabetic Control and Postprandial Gut Hormone Responses

Publisher Website
Google Scholar
Abstract
Twelve sulphonylurea‐treated Type 2 diabetic patients underwent treatment for 2‐week periods with the absorbable α‐glucosidase inhibitor BAY m1099 (50 mg thrice daily) and with guar granules (5 g thrice daily) separately and together in a sequence‐randomized double‐blind placebo‐controlled study. BAY m1099 and guar reduced the mean fasting plasma glucose from 10.0 ± 0.7 mmol I−1 to 8.7 ± 0.5 (p < 0.05) and 8.3 ± 0.7 mmol I−1 (p < 0.01), respectively. Both agents also lowered home‐monitored postprandial blood glucose, with BAY m1099 exerting the greater effect. Guar, but not BAY m1099, lowered serum cholesterol from 5.43 ± 0.52 to 5.29 ± 0.31 mmol I−1 (p < 0.05). BAY m1099 reduced the test breakfast plasma responses of glucose (p < 0.001) and gastric inhibitory polypeptide (GIP, p < 0.01) and increased those of peptide tyrosine‐tyrosine (p < 0.05) and motilin (p p < 0.05) and increased the response of neurotensin (p < 0.05). Combining treatments gave no further reduction of postprandial blood glucose concentration and was associated with an increased incidence and severity of gastrointestinal side‐effects.